Biohaven, Bexorg Partner to Accelerate CNS Drug Discovery Using Novel Whole-Brain Platform

Biohaven Ltd. (NYSE:BHVN) is one of the best low priced pharma stocks to buy now. Earlier on June 10, Bexorg Inc., which is a techbio company focused on central nervous system/CNS disorders, announced a multi-program research collaboration with Biohaven. The partnership aims to identify, de-risk, and advance next-gen therapies for CNS disorders.

This collaboration centers on Bexorg’s novel whole-brain discovery platform. The unique technology was developed by Bexorg’s founders at Yale University and is capable of perfusing isolated, cadaver human and pig brains with custom-made artificial blood. This process restores metabolic and molecular activity for prolonged periods, which allows Bexorg to extract high-resolution transcriptomic, proteomic, and metabolic insights in disease-relevant states.

By using this information, Bexorg is building physiologically relevant datasets in human neurodegeneration, which are crucial for ML and AI-centered CNS drug discovery and development. The platform’s ability to collect longitudinal data provides an advantage over other preclinical models in neuroscience by enabling the validation of new targets and biomarkers and the understanding of pharmacokinetic and pharmacodynamic profiles.

Biohaven Ltd. (NYSE:BHVN) discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide.

While we acknowledge the potential of BHVN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.